DEVELOPMENT OF AMYLOID B-PROTEIN OLIGOMERIZATION INHIBITORS
B 淀粉样蛋白寡聚化抑制剂的开发
基本信息
- 批准号:7663803
- 负责人:
- 金额:$ 25.38万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:AffinityAlzheimer&aposs DiseaseAmyloidAmyloid beta-ProteinBackBiologicalBiological AssayC-terminalCell LineCharacteristicsCircular DichroismClassificationClinicalCollaborationsDataDevelopmentExperimental ModelsFutureGoalsKnowledgeLaboratoriesLengthLifeLigandsLinkMass Spectrum AnalysisModificationMolecular ConformationNeuronsPatternPeptidesPreparationProcessProteinsProteolysisRelative (related person)ResolutionRoleScreening procedureSideSilicon DioxideSolubilitySolutionsSpectrometryStructureStructure-Activity RelationshipSurfaceTestingToxic effectabeta oligomeraqueousbasecrosslinkdata modelingdesignenzyme substratefeedinginhibitor/antagonistion mobilitymemberneurotoxicneurotoxicitynovelpreventprogramsreceptorthree dimensional structure
项目摘要
We hypothesize that soluble amyloid beta-protein (Abeta) oligomers are key effectors of neurotoxicity and
may be a primary cause of Alzheimer's disease (AD). Consequently, inhibition of Abeta Oligomerization
is an attractive strategy for preventing and treating AD. We propose to use a systematic, rational
design approach for preparation and structure-activity studies of Abeta Oligomerization inhibitors. We
will focus our efforts on inhibitors of early Abeta(1-42) oligomers termed "paranuclei." We choose early
Abeta(1-42) oligomers as our primary target because Abeta(1-42) is particularly linked to AD and because
inhibition of early assembly of Abeta(1-42) will alleviate the neurotoxic effects, both of the oligomers
themselves and of the larger neurotoxic assemblies, protofibrils and fibrils, for which paranuclei are
precursors. Our design in based on recent experimental and modeling data that delineate structural
features of paranucleus assembly, including primary-quaternary structure relationships and
conformation of the C-terminus of Abeta(1-42). This region is responsible directly for the enhanced
toxicity and distinct Oligomerization pattern of Abeta(1-42) relative to the more abundant alloform,
Abeta(1-40). The inhibitor design process is tightly integrated with the structural and biological projects
within the overall Program. The design process not only will benefit from the structural data
generated by the Program members, but also will feed back into structural studies and provide
further understanding of how particular regions and residues in Abeta interact with each other to form
oligomers.
我们假设可溶性淀粉样蛋白(Abeta)低聚物是神经毒性和神经毒性的关键效应物
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
GAL BITAN其他文献
GAL BITAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('GAL BITAN', 18)}}的其他基金
Biomarkers for parkinsonian disorders in CNS-originating extracellular vesicles
中枢神经系统来源的细胞外囊泡中帕金森病的生物标志物
- 批准号:
10662918 - 财政年份:2023
- 资助金额:
$ 25.38万 - 项目类别:
Can diagnostic biomarkers for parkinsonian syndromes be measured in postmortem blood samples?
可以在死后血液样本中测量帕金森综合症的诊断生物标志物吗?
- 批准号:
10572535 - 财政年份:2023
- 资助金额:
$ 25.38万 - 项目类别:
Investigation of the Effect of Structural Modifications of Tau on Assembly State and Seeding
Tau 结构修饰对组装状态和播种影响的研究
- 批准号:
10241797 - 财政年份:2017
- 资助金额:
$ 25.38万 - 项目类别:
Misfolded protein clearance enhancers for Alzheimers therapy
用于治疗阿尔茨海默病的错误折叠蛋白清除增强剂
- 批准号:
9267131 - 财政年份:2015
- 资助金额:
$ 25.38万 - 项目类别:
Misfolded protein clearance enhancers for Alzheimers therapy
用于治疗阿尔茨海默病的错误折叠蛋白清除增强剂
- 批准号:
9139393 - 财政年份:2015
- 资助金额:
$ 25.38万 - 项目类别:
Misfolded protein clearance enhancers for Alzheimers therapy
用于治疗阿尔茨海默病的错误折叠蛋白清除增强剂
- 批准号:
9331297 - 财政年份:2015
- 资助金额:
$ 25.38万 - 项目类别:
DEVELOPMENT AMYLOID B-PROTEIN OLIGOMERIZATION INHIBITORS
淀粉样 B 蛋白寡聚化抑制剂
- 批准号:
7112795 - 财政年份:2006
- 资助金额:
$ 25.38万 - 项目类别:
DEVELOPMENT OF AMYLOID B-PROTEIN OLIGOMERIZATION INHIBITORS
B 淀粉样蛋白寡聚化抑制剂的开发
- 批准号:
8114005 - 财政年份:
- 资助金额:
$ 25.38万 - 项目类别:














{{item.name}}会员




